In today’s environment, biologics developers are under increased pressure to balance supply chain resilience, cost efficiency regulatory complexity, and speed to market. This is why Rezon Bio and Chime Biologics are collaborating to offer a geographically diversified, dual-source manufacturing strategy, spanning Europe and Asia, helping clients build more resilient, and flexible supply strategies without operational complexity.
What does this mean for biologics developers?
- Supply chain resilience through manufacturing across multiple regions
- No dependency on a single geography, less operational and geopolitical uncertainty
- Access to price-competitive manufacturing capacity in highly regulated markets
- Fully integrated development, seamless technology transfer, and manufacturing across continents
- De-risked FDA and EMA interactions
- Single point of contact with seamless execution under one project governance structure and management
- Commercial flexibility with manufacturing options that evolve alongside your program
For Asian biopharma and biotech companies, this collaboration provides access to price-competitive European manufacturing, global regulatory expertise, and a streamlined pathway to support biologics development and commercialization in highly regulated markets.
For US and European companies, it provides access to cost-efficient manufacturing capacity in Asia, increased supply chain resilience through geographic diversification, and greater flexibility to support global development of commercialization strategies.
By combining complementary strengths across regions, we aim to offer clients greater flexibility and resilience in their development and manufacturing strategies, while maintaining the independence, quality standards, and client-centric approach that define Rezon Bio.
Interested in learning how a dual-source manufacturing strategy could support your next biologics program?
